Pharmacological protection of vascular endothelium in acute COVID-19.
Journal
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
ISSN: 1899-1505
Titre abrégé: J Physiol Pharmacol
Pays: Poland
ID NLM: 9114501
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
04
03
2022
accepted:
30
04
2022
entrez:
21
8
2022
pubmed:
22
8
2022
medline:
24
8
2022
Statut:
ppublish
Résumé
Since the beginning of the COVID-19 pandemic, there has been an urgent need to find effective treatment. It is widely known that virus attacks and damages mostly the lungs, but also infect vascular endothelial cells. Therefore, the protection of the endothelium is a promising target in the therapy of COVID-19 and its complications. In this review article, we focused on several groups of drugs with potential to protect the endothelium. The most promising ones are angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, drugs targeting angiotensin-converting enzyme 2, heparins, sulodexide, acetylsalicylic acid, statins, tocilizumab, baricitinib, and defibrotide. Although the short period of trials and the lack of data necessitate further research, endothelial protection remains a promising target for COVID-19 therapy.
Identifiants
pubmed: 35988926
doi: 10.26402/jpp.2022.2.01
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM